Heparin-Induced Thrombocytopenia
Authors:
- 1 May 2000
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 16 (5) , 351-364
Abstract
Heparin therapy may sometimes be seriously complicated by heparin-induced thrombocytopenia (HIT). Heparin use for treatment and prevention of thromboembolism is more common in the elderly and that may be the reason why HIT is reported more frequently in this group of patients. The first approach in the management of HIT is awareness of this disorder. The morbidity and mortality associated with HIT may be reduced by avoiding unnecessary heparin exposure, by reducing the duration of heparinisation and by using low molecular weight heparins rather than unfractionated heparin. A decrease from baseline values of at least 30% in the platelet count, any unexplained thrombotic event and the finding of a white clot at thrombectomy are clinical warning signs that should alert physicians to a possible diagnosis of HIT. Indeed, early clinical recognition of HIT may sometimes prevent the severe complications associated with this disorder. Objective confirmation of the diagnosis of HIT is difficult because none of the available biological tests possess 100% sensitivity or 100% specificity. It is, however, possible to optimise the performances of the functional assay, mainly the platelet aggregation test (PAT), by following the manoeuvres described by different investigators. The use of 2 classes of assay (functional and antigen assays) and repeat testing on another day can avoid misdiagnosis of HIT. An alternative parenteral anticoagulant treatment is most often mandatory after heparin withdrawal. Danaparoid sodium and lepirudin are 2 drugs that are currently available for the treatment of HIT, and the efficacy of argatroban needs to be confirmed in greater numbers of patients with HIT. The use of these drugs has contributed to the reduction in the mortality and morbidity associated with HIT.Keywords
This publication has 80 references indexed in Scilit:
- DanaparoidDrugs, 1997
- Heparin-induced thrombocytopenia: an under-diagnosed syndrome?Platelets, 1997
- Pathogenicity of IgA and/or IgM antibodies to heparin–PF4 complexes in patients with heparin‐induced thrombocytopeniaBritish Journal of Haematology, 1996
- FAILURE OF ORGARAN THERAPY IN A PATIENT WITH A PREVIOUS HEPARIN‐INDUCED THROMBOCYTOPENIA SYNDROMEBritish Journal of Haematology, 1995
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Heparin‐associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharidesBritish Journal of Haematology, 1993
- Immune Endothelial-Cell Injury in Heparin-Associated ThrombocytopeniaNew England Journal of Medicine, 1987
- Das heparin-induzierte Thrombose-Thrombozytopenie-SyndromDMW - Deutsche Medizinische Wochenschrift, 1987
- Heparin induced thrombocytopenia. variable dependent platelet aggregating factorPathology, 1983
- Effect of Heparin and Heparin Fractions on Platelet AggregationJournal of Clinical Investigation, 1980